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Prostate cancer risk related to foods, food groups,
macronutrients and micronutrients derived from the UK
Dietary Cohort Consortium food diaries
JA Lane1,2, SE Oliver3, PN Appleby4, MAH Lentjes5, P Emmett1, D Kuh6, A Stephen6,7, EJ Brunner8, MJ Shipley8, FC Hamdy9, DE Neal10,
JL Donovan1, K-T Khaw5,11 and TJ Key4
BACKGROUND/OBJECTIVES: The inﬂuence of dietary factors remains controversial for screen-detected prostate cancer and
inconclusive for clinically detected disease. We aimed to examine these associations using prospectively collected food diaries.
SUBJECTS/METHODS: A total of 1,717 prostate cancer cases in middle-aged and older UK men were pooled from four prospective
cohorts with clinically detected disease (n=663), with routine data follow-up (means 6.6–13.3 years) and a case-control study with
screen-detected disease (n=1054), nested in a randomised trial of prostate cancer treatments (ISCTRN 20141297). Multiple-day food
diaries (records) completed by men prior to diagnosis were used to estimate intakes of 37 selected nutrients, food groups and items,
including carbohydrate, fat, protein, dairy products, ﬁsh, meat, fruit and vegetables, energy, ﬁbre, alcohol, lycopene and selenium. Cases
were matched on age and diary date to at least one control within study (n=3528). Prostate cancer risk was calculated, using
conditional logistic regression (adjusted for baseline covariates) and expressed as odds ratios in each quintile of intake (±95%
conﬁdence intervals). Prostate cancer risk was also investigated by localised or advanced stage and by cancer detection method.
RESULTS: There were no strong associations between prostate cancer risk and 37 dietary factors.
CONCLUSIONS: Prostate cancer risk, including by disease stage, was not strongly associated with dietary factors measured by food
diaries in middle-aged and older UK men.
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INTRODUCTION
Prostate cancer is the most commonly detected life-threatening
cancer among men in most Western countries, and accounted for
over 300 000 deaths worldwide in 2012.1 The incidence of
prostate cancer is increasing worldwide, largely due to screening
programmes, and has doubled in the UK from 1984 to 2007.2 The
established risk factors for prostate cancer are age, ethnicity,
family history of the disease and some genetic factors.3
Increasingly, obesity has been linked to aggressive prostate cancer
risk.4 Prostate cancer incidence and mortality varies globally,
suggesting that diet and environmental factors may explain some
of the geographic variation.5 Several hypotheses have been
explored, including that prostate cancer risk may be elevated by
diets rich in meat, dairy products or fat, and may be lowered by
diets high in ﬁbre, fruit, vegetables and various micronutrients.5,6
The epidemiological evidence for selenium and vitamin E was
judged sufﬁcient to commence a randomised supplementation
trial, but this was stopped early due to no beneﬁt,7 with
subsequent follow-up indicating an increased prostate cancer risk
with vitamin E supplementation.8 The American Institute for
Cancer Research/World Cancer Research Fund (AICR/WCRF) guide-
lines currently identify the carotenoid lycopene, a pigment found
in tomatoes and other fruits as having a ‘probable’ protective
effect on prostate cancer risk,5 whereas diets rich in calcium were
classed as ‘probably’ increasing prostate cancer risk.
Epidemiological studies of diet and cancer have predominantly
utilised food frequency questionnaires (FFQ) to measure intake.9
The greater measurement error of some dietary items associated
with FFQs in comparison to measurement by multiple-day food
diaries (records) has been suggested to account for some null
ﬁndings for diet and cancer risk,10,11 although this is contested.12
The UK Dietary Cohort Consortium was established in 200613 to
understand diet and cancer relationships, using up to eight
population-based prospective studies with food diaries (records).
We have utilised the consortium data to analyse prostate cancer
risk in relation to dietary intake of food groups (meat, ﬁsh, dairy
products, fruit and vegetables), macronutrients and micronutrients
potentially associated with disease.
PARTICIPANTS AND METHODS
Study population
Table 1 summarises the ﬁve UK Dietary Cohort Consortium studies that
contributed data: European Prospective Investigation into Cancer and
Nutrition (EPIC)-Norfolk,14 EPIC-Oxford,15 Medical Research Council
National Survey of Health and Development (NSHD),16 Prostate testing
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for cancer and Treatment study (ProtecT17) and Whitehall II.18 Two
additional cohorts only recruited females and one focused on vegetarians,
so they were excluded from this analysis. The study designs, ethical
approvals and conduct have been described in detail elsewhere.14–18
Information on demographic and lifestyle factors was collected either
during participant interviews or by using questionnaires administered prior
to, or contemporaneously with, the completion of the food diary.
Ascertainment of prostate cancer and follow-up
Four prospective cohort studies (EPIC-Norfolk, EPIC-Oxford, NSHD and
Whitehall II) obtained prostate cancer diagnoses through record linkage
with the UK National Health Service Ofﬁce for National Statistics and
cancer registries. Case participants were individuals who were undiag-
nosed with cancer (except non-melanoma skin cancer) at the time of diary
completion and who were diagnosed with prostate cancer at least
12 months later (6 months in EPIC-Oxford) but before the closure date for
each cohort (latest date of complete follow-up for cancer incidence and
vital status, which was the same for cases and controls) (Table 1). The ninth
and tenth revisions of the International Statistical Classiﬁcation of Diseases,
Injuries and Causes of Death (ICD) were used to deﬁne prostate cancer
(codes 185 or C61). Clinical staging data from cancer registries (where
available) utilised the tumour, nodes and metastasis system, with T1-T2 (N0
or Nx, M0 or Mx) categorised as localised disease and T3-T4 as advanced
disease; Gleason grade was unavailable in most cohorts, where cases were
identiﬁed through routine data record linkage, so this clinical factor was
excluded from all analyses.
ProtecT is an ongoing randomised controlled trial of treatments in men
diagnosed with localised prostate cancer following the community-based
prostate-speciﬁc antigen (PSA) testing in nine centres across the UK, which
will publish trial outcomes in 2016 (ISCTRN20141297).17 Men aged 50–69
years registered at randomly selected general practices were invited to
attend recruitment/PSA-testing clinics. There was no selection by
symptoms or PSA status (13% had received a prior test) and the UK does
not have a prostate cancer screening programme.19 Around 40% of invited
men attended clinics between 2003 and 2009. Food diaries were
distributed by trial nurses at recruitment to men also participating in the
ProMPT (Prostate Mechanisms of Progression and Treatment) translational
study, with over 75% returned prior to receipt of PSA results. Participants
with an elevated PSA result (⩾3.0 ng/ml, a threshold linked to
contemporary clinical practice in the UK) underwent 10-core prostate
biopsies (87% of those eligible received a biopsy) and those with a
negative biopsy were offered a second biopsy.
Selection of matched controls
Cases were matched within an individual study with up to four control
participants selected at random from all eligible potential controls within
the matching criteria. Cohort controls were men without notiﬁed prostate
cancer at closure date for follow-up, whereas ProtecT controls either had a
PSA result of o3.0 ng/ml or negative prostatic biopsies. Matching criteria
within each study were age (generally ± 3 years from diary commence-
ment, ± 6 months for EPIC-Oxford and ±5 years for ProtecT) and diary
completion date (generally ± 3 months, ± 6 months for EPIC-Oxford).
Measurement of food and nutrient intake
Seven-day food diaries (ﬁve-day in NSHD) were completed at recruitment
(EPIC-Norfolk and ProtecT) or ~ 6 months later (EPIC-Oxford) or at second
follow-up (Whitehall II) or when participants were 43 years old (NSHD).
Participants were asked to record all food and drinks consumed at the
times speciﬁed (for example, breakfast and lunch), with photographs of
food items to aid estimation of portion sizes. Information from food diaries
was coded to derive nutrient intakes based on national food composition
tables contemporaneous with diary completion dates as described
previously.13 The food groups were deﬁned by the consortium: red meat,
processed meat, poultry, white and oily ﬁsh, and included disaggregation
of dishes containing constituent foods;20 additional food groups studied
were yogurt, cheese and milk, which were also used to calculate dairy
protein intake (sum of those products, dairy creams, chocolate and milk
drinks, ice cream, dairy sauces, chocolate desserts and other animal milks).
EPIC-Norfolk, EPIC-Oxford, Whitehall II and 1107 ProtecT diaries were
coded with the Data Into Nutrients for Epidemiological Research (DINER)
data entry21 and Data Into Nutrients for Epidemiological Research Moving
Onwards (DINERMO) processing software,22 whereas NSHD and 1208 of
the ProtecT diaries (coded before joining the consortium but case/control
pairs coded with the same software) used the Diet In Data Out (DIDO)
programme.23 Some NSHD (100) and ProtecT (99) diaries were processed
with DIDO and DINERMO, and there was good agreement for total energy,
carbohydrate, fat, calcium, total sugars and starch intakes. The DIDO
programme gave lower values for alcohol intake than DINERMO, which we
hypothesised reﬂected UK alcohol measures having increased over time,
so the DIDO estimates were retained as they were determined
contemporaneously to diary completion.
Statistical methods
The pre-speciﬁed consortium analysis plan for all cancers deﬁned the
selection and categorisation of dietary exposures and confounders with
lycopene and selenium added to the prostate plan based on AICR/WCRF
guidelines for prostate cancer prevention.5 Analyses used all available data;
all tests were two sided with no adjustment for multiple comparison and
included diaries with incomplete days. No exclusions were made on the
basis of reported levels of energy intake; only 16 (0.3%) participants fell
outside recommended cutoffs (o800 kcal or 44000 kcal in men).24
Conditional logistic regression was used to calculate odds ratios (ORs) and
95% conﬁdence intervals (95% CI) for prostate cancer risk according to
quintiles of intake of 37 dietary variables (quintiles calculated on intakes
combined across studies for all participants), with the P value for trend test
being of principal interest. There was a high proportion of non-consumers
of oily ﬁsh (ﬁrst and second quintiles were combined) and yoghurt (ﬁrst
three combined), whereas ﬁve pre-speciﬁed cut-points were used for
alcohol consumption (o1, 1–9, 10–19, 20–39, 40 and above g/d). To test
for trends in prostate cancer risk across the distribution of intakes, we
calculated the ORs (95% CI) for a 1 s.d. increase in nutrient intake with the
P value being obtained by comparing the ratio of the logarithm of the OR
and its standard error to the normal distribution.
As age is a risk factor for prostate cancer, age was utilised as a
continuous variable in the regression models. Additional adjustment was
made for other potential confounders, that is, total energy intake
Table 1. Characteristics of the Dietary Cohort Consortium studies
Studya Participants Diary
completion
(years)
Final
follow-up
date
Follow-up
duration
(years)b
Prostate
cancer
cases (n)
Clinical stage
(n, advanced/
localised/
unknown)
Controls (n) Control matching Age at diary
completion
(years)b
Age at diary
completion
Month of
diary
completion
EPIC-Norfolk Population 1993–1998 31/12/2009 7.3 (3.2) 439 105/251/83 1752 ± 3 years ± 3 months 64.8 (7.7)
EPIC-Oxford Population and vegetarians 1993–1999 31/12/2007 6.6 (2.7) 125 22/73/30 125 ± 6 months ± 6 months 64.6 (8.0)
NSHD Born 1946 1989–1990 31/12/2008 13.3 (3.3) 15 0/0/15 60 ± 3 years ± 3 months 43.5 (0.2)
ProtecT Population 2003–2009 29/04/2009 0.2 (0.3) 1054 99/953/2 1261 ± 5 years ± 3 months 62.9 (4.7)
Whitehall II Civil servants 1991–1993 29/11/2005 9.0 (2.9) 84 0/0/84 330 ± 3 years ± 3 months 54.8 (4.8)
aAbbreviations: EPIC, European Prospective Investigation into Cancer and Nutrition; NSHD, National Survey of Health and Development; ProtecT, Prostate
testing for cancer and Treatment. bMean (s.d.) in years.
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(quintiles), body mass index (BMI: o22.5, 22.5–24.9, 25.0–27.4, 27.5–29.9,
30.0 and above, unknown kg/m2), smoking status (never, previous, current,
unknown), marital status (married or cohabiting, single including divorced
and separated, unknown), self-reported diabetes at recruitment (no, yes,
unknown) and a residential area-based measure of material deprivation
(quartiles of Townsend Score).25 Unknown values were categorised as
missing (BMI 6%, smoking 5%, marital status 1%, diabetes 8% and
socioeconomic measure 3%). The majority of epidemiological evidence on
diet and prostate cancer risk relates to studies in which cases were
identiﬁed clinically, and to enable comparison with this pre-existing
literature disease risk was also assessed for the cohort studies combined
(that is, predominantly clinically diagnosed disease) and for PSA-detected
disease (ProtecT study, akin to screening) and reported as risk per 1 s.d.
increase in dietary intake. Disease-diet associations were also examined
and reported in the same way for localised and advanced prostate cancer.
Analyses were performed using Stata version 10.26
RESULTS
Study and participant characteristics
In total, 1717 men diagnosed with prostate cancer were compared
with 3528 matched controls without prostate cancer (Table 1).
There were 1277 cases of localised prostate cancer (74.4%) and
226 advanced cases (13.2%), whereas for 214 cases the disease
stage at diagnosis was unknown (12.5%). Table 2 summarises the
clinical and socio-demographics of participants by prostate cancer
status. Participants had a mean age of 62 years at recruitment,
were slightly overweight on average (BMI 26.3 kg/m2) and over
85% were married or cohabiting.
Dietary intake and overall prostate cancer risk
The unadjusted intakes of dietary factors for cases and controls
combined for the ﬁve studies are shown in Table 3. There were
some modest differences in consumption between cases and
controls; namely, oily ﬁsh, red meat and protein (each 2% more in
cases), energy (1.5% less), cheese (3% less), yoghurt (12% more),
alcohol (4% more), fruit and vegetables (1% less), vitamin C (2%
more), calcium (1% more), retinol (1% less) and selenium (4%
more). The adjusted risk estimates for overall prostate cancer
incidence showed no statistically signiﬁcant linear trends across
the distributions of the 37 dietary factors (Table 4).
Table 2. Baseline characteristics of prostate cancer cases and controls
pooled across ﬁve studies
Characteristica Controls (n= 3528) Cases (n=1717)
Age at diary completion (years) 62.7 (7.5) 63.0 (6.5)
Height (m)b 1.75 (0.07) 1.75 (0.07)
Weight (kg)c 80.7 (11.6) 80.8 (11.7)
Body mass index (kg/m2) 26.4 (3.3) 26.3 (3.3)
Body mass index, categories, n (% known)
o22.5 334 (9.9) 171 (10.8)
22.5–24.9 822 (24.5) 428 (27.1)
25.0–27.4 1100 (32.7) 487 (30.8)
27.5–29.9 643 (19.1) 291 (18.4)
⩾ 30.0 462 (13.7) 203 (12.8)
Missing, n (% all) 167 (4.7) 137 (8.0)
Smoking status, n (% known)
Never 1116 (33.1) 605 (37.7)
Former 1873 (55.5) 821 (51.2)
Current 383 (11.4) 177 (11.0)
Missing, n (% all) 156 (4.4) 114 (6.6)
Marital status, n (% known)
Married or cohabiting 3030 (86.4) 1500 (88.0)
Unmarried 478 (13.6) 205 (12.0)
Missing, n (% all) 20 (0.6) 12 (0.7)
Diabetes, n (% known)
No diabetes 3121 (94.4) 1462 (95.1)
Diabetes (self-reported) 185 (5.6) 76 (4.9)
Missing, n (% all) 222 (6.3) 179 (10.4)
Townsend material deprivation score, n (% known)
Low (richest) 817 (24.6) 403 (25.5)
Medium-low 864 (26.0) 370 (23.4)
Medium-high 837 (25.2) 383 (24.3)
High (poorest) 802 (24.2) 422 (26.7)
Missing, n (% all) 208 (5.9) 139 (8.1)
aValues are unadjusted means (s.d. except where indicated) combined for
ﬁve studies. bMissing for 151 (4.3%) controls, 115 (6.7%) cases. cMissing for
157 (4.5%) controls, 131 (7.6%) cases.
Table 3. Consumption of food groups, foods, macronutrients and
micronutrients pooled across ﬁve studies
Dietary intake and unitsa Controls
(n= 3528)
Prostate
cancer cases
(n= 1717)
Food groups
Red meat (g/d) 41.6 (31.3) 42.3 (31.2)
Processed meat (g/d) 27.8 (22.0) 27.6 (21.2)
Red and processed meat (g/d) 69.4 (39.8) 70.0 (39.8)
Poultry (g/d) 25.7 (24.8) 26.0 (25.6)
White ﬁsh (g/d) 15.9 (17.2) 15.3 (17.7)
Oily ﬁsh (g/d) 14.7 (21.2) 15.6 (22.8)
Milk (g/d) 207 (143) 205 (146)
Cheese (g/d) 17.4 (17.2) 16.0 (17.2)
Yogurt (g/d) 24.1 (43.2) 26.9 (47.0)
Fruit and vegetables (g/d) 313 (174) 310 (169)
Total energy intake (MJ/d) 9.12 (2.11) 8.98 (2.07)
Macronutrients
Protein (% energy) 15.4 (2.6) 15.7 (2.7)
Protein from dairy products (% energy) 2.6 (1.3) 2.6 (1.4)
Carbohydrate (% energy) 45.6 (6.7) 45.2 (6.9)
Total fat (% energy) 33.2 (5.4) 32.9 (5.5)
Saturated fat (% energy) 12.4 (3.0) 12.1 (3.1)
Monounsaturated fat (% energy) 11.5 (2.1) 11.4 (2.1)
Polyunsaturated fat (% energy) 6.2 (1.7) 6.1 (1.8)
n-6 fatty acids (% energy)* 5.3 (1.8) 5.2 (1.7)
n-3 fatty acids (% energy)* 0.69 (0.26) 0.71 (0.30)
Ratio n-6:n-3b 8.4 (3.7) 8.2 (3.8)
Alcohol (g/d) 18.4 (21.4) 19.2 (21.9)
Dietary ﬁbre (g/d) 15.9 (6.0) 15.6 (6.0)
Micronutrients
Retinol (μg/d) 700 (1072) 656 (1020)
Carotene (μg/d)* 2675 (1556) 2773 (1597)
Lycopene (μg/d)* 1485 (1983) 1481 (1968)
Vitamin B6 (mg/d) 2.25 (0.66) 2.31 (0.68)
Folate (μg/d) 293 (90) 295 (89)
Vitamin B12 (μg/d) 5.68 (3.97) 5.64 (3.96)
Vitamin C (mg/d) 87.7 (51.6) 89.2 (55.0)
Vitamin D (μg/d) 3.82 (2.76) 3.88 (2.80)
Vitamin E (mg/d) 11.0 (4.9) 10.8 (5.0)
Calcium (mg/d) 896 (283) 887 (283)
Iron (mg/d) 13.1 (4.0) 13.0 (3.9)
Magnesium (mg/d) 322 (91) 323 (90)
Selenium (μg/d) 71.0 (31.4) 73.8 (40.1)
Zinc (mg/d) 9.52 (2.53) 9.52 (2.55)
aValues are unadjusted means or percentages (s.d.). bUnknown for some
participants.
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Table 4. Odds ratios for prostate cancer diagnosis by food groups, foods and nutrient consumption
Food group, food or nutrienta Food or nutrient intake (increasing quintiles except where indicated) P value for trendb
1 (referent) 2 3 4 5
Red meat (g/d)
Cut-point 14.6 30.4 45.4 65.3
Cases/controls 345/688 330/735 331/718 355/694 356/693
Odds ratio (95% CI) 1.00 0.90 (0.74–1.09) 0.93 (0.77–1.14) 1.02 (0.84–1.24) 0.99 (0.81–1.21) 0.99
Processed meat (g/d)
Cut-point 8.6 18.9 29.3 43.7
Cases/controls 333/716 342/710 347/699 340/709 355/694
Odds ratio (95% CI) 1.00 1.06 (0.87–1.29) 1.10 (0.91–1.34) 1.11 (0.91–1.35) 1.14 (0.93–1.39) 0.98
Red and processed meat (g/d)
Cut-point 37.2 56.8 75.9 99.7
Cases/controls 344/705 341/708 321/728 349/700 362/687
Odds ratio (95% CI) 1.00 1.03 (0.84–1.26) 0.95 (0.78–1.16) 1.07 (0.88–1.31) 1.05 (0.86–1.29) 0.99
Poultry (g/d)
Cut-point 0.2 15.3 27.1 43.2
Cases/controls 388/718 312/687 323/716 339/713 355/694
Odds ratio (95% CI) 1.00 0.86 (0.71–1.05) 0.87 (0.72–1.06) 0.89 (0.74–1.08) 0.95 (0.79–1.15) 0.78
White ﬁsh (g/d)
Cut-point 0.2 9.3 16.5 27.1
Cases/controls 626/1224 86/161 351/708 286/690 368/745
Odds ratio (95% CI) 1.00 1.04 (0.77–1.40) 1.02 (0.86–1.21) 0.92 (0.77–1.10) 1.10 (0.93–1.31) 0.54
Oily ﬁsh (g/d)c
Cut-point — 0.2 12.9 28.6
Cases/controls 788/1603 — 213/511 350/728 366/686
Odds ratio (95% CI) 1.00 — 0.89 (0.73–1.08) 0.93 (0.79–1.10) 1.00 (0.85–1.18) 0.83
Milk (g/d)
Cut-point 89 154 216 308
Cases/controls 349/699 343/707 350/699 340/709 335/714
Odds ratio (95% CI) 1.00 1.05 (0.87–1.28) 1.05 (0.86–1.27) 1.04 (0.86–1.27) 1.04 (0.85–1.28) 0.33
Cheese (g/d)
Cut-point 2.6 9.9 16.5 28.4
Cases/controls 372/674 364/687 340/710 326/733 315/724
Odds ratio (95% CI) 1.00 1.04 (0.86–1.26) 0.95 (0.78–1.15) 0.89 (0.73–1.08) 0.95 (0.77–1.16) 0.25
Yogurt (g/d)d
Cut-point — — 0.4 49.3
Cases/controls 1005/2149 — — 350/690 362/689
Odds ratio (95% CI) 1.00 — — 1.09 (0.93–1.28) 0.92 (0.79–1.08) 0.57
Fruit and vegetables (g/d)
Cut-point 171 246 325 434
Cases/controls 343/706 357/692 334/715 336/713 347/702
Odds ratio (95% CI) 1.00 1.10 (0.91–1.34) 0.99 (0.81–1.21) 1.04 (0.85–1.27) 1.05 (0.85–1.28) 0.66
Energy (MJ/d)
Cut-point 7.33 8.45 9.47 10.76
Cases/controls 362/687 366/683 340/709 320/729 329/720
Odds ratio (95% CI) 1.00 1.09 (0.90–1.32) 1.00 (0.82–1.21) 0.97 (0.79–1.18) 1.11 (0.91–1.36) 0.72
Protein (% energy)
Cut-point 13.3 14.7 15.9 17.5
Cases/controls 306/743 318/731 363/686 352/697 378/671
Odds ratio (95% CI) 1.00 1.00 (0.82–1.23) 1.16 (0.95–1.42) 1.02 (0.83–1.25) 1.03 (0.83–1.29) 0.68
Dairy protein (% energy)
Cut-point 1.5 2.1 2.7 3.5
Cases/controls 372/677 326/723 332/717 331/718 356/693
Odds ratio (95% CI) 1.00 0.88 (0.73–1.07) 0.89 (0.73–1.08) 0.91 (0.75–1.11) 0.97 (0.80–1.18) 0.95
Carbohydrate (% energy)
Cut-point 39.9 44.2 47.3 51.0
Cases/controls 358/691 357/692 346/703 323/726 333/716
Odds ratio (95% CI) 1.00 1.03 (0.85–1.25) 1.03 (0.85–1.25) 0.93 (0.76–1.13) 1.04 (0.85–1.28) 0.59
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Table 4. (Continued)
Food group, food or nutrienta Food or nutrient intake (increasing quintiles except where indicated) P value for trendb
1 (referent) 2 3 4 5
Total fat (% energy)
Cut-point 28.6 31.8 34.6 37.5
Cases/controls 368/681 342/707 340/709 338/711 329/720
Odds ratio (95% CI) 1.00 0.95 (0.78–1.15) 0.98 (0.81–1.19) 0.99 (0.81–1.21) 1.00 (0.82–1.21) 0.83
SFA (% energy)
Cut-point 9.9 11.3 12.8 14.6
Cases/controls 384/665 336/713 343/706 323/726 331/718
Odds ratio (95% CI) 1.00 0.96 (0.79–1.16) 1.03 (0.85–1.25) 1.01 (0.83–1.23) 1.04 (0.85–1.27) 0.98
MUFA (% energy)
Cut-point 9.8 10.9 12.0 13.1
Cases/controls 353/696 349/700 347/702 329/720 339/710
Odds ratio (95% CI) 1.00 1.07 (0.89–1.30) 1.08 (0.89–1.31) 1.07 (0.88–1.30) 1.04 (0.86–1.26) 0.67
PUFA (% energy)
Cut-point 4.8 5.6 6.4 7.4
Cases/controls 367/682 333/716 343/706 347/702 327/722
Odds ratio (95% CI) 1.00 0.93 (0.77–1.13) 1.04 (0.85–1.26) 1.02 (0.84–1.24) 0.98 (0.80–1.19) 0.78
n-6 fatty acids (% energy)e
Cut-point 4.0 4.7 5.4 6.5
Cases/controls 235/593 232/596 254/573 239/589 216/611
Odds ratio (95% CI) 1.00 0.91 (0.72–1.14) 1.04 (0.82–1.31) 0.98 (0.78–1.24) 0.86 (0.68–1.09) 0.42
n-3 fatty acids (% energy)e
Cut-point 0.51 0.60 0.71 0.86
Cases/controls 246/582 213/615 234/593 231/597 252/575
Odds ratio (95% CI) 1.00 0.80 (0.64–1.01) 0.91 (0.72–1.14) 0.85 (0.68–1.07) 0.91 (0.72–1.14) 0.72
Ratio n-6:n-3e
Cut-point 5.5 6.8 8.3 10.7
Cases/controls 243/585 263/565 228/599 223/605 219/608
Odds ratio (95% CI) 1.00 1.15 (0.92–1.44) 0.99 (0.79–1.24) 0.93 (0.74–1.17) 0.94 (0.74–1.18) 0.75
Alcohol (g/d)f
Cut-point 1.0 10.0 20.0 40.0
Cases/controls 362/780 389/871 348/623 374/790 244/464
Odds ratio (95% CI) 1.00 0.98 (0.81–1.18) 1.07 (0.88–1.30) 0.93 (0.77–1.12) 1.02 (0.82–1.28) 0.93
Dietary ﬁbre (g/d)
Cut-point 10.9 13.6 16.3 20.1
Cases/controls 360/689 335/714 342/707 351/698 329/720
Odds ratio (95% CI) 1.00 0.93 (0.76–1.13) 0.89 (0.73–1.10) 0.98 (0.80–1.21) 0.90 (0.72–1.12) 0.34
Retinol (μg/d)
Cut-point 234 325 439 654
Cases/controls 359/690 351/698 337/712 334/715 336/713
Odds ratio (95% CI) 1.00 0.98 (0.81–1.19) 0.94 (0.77–1.15) 1.00 (0.81–1.24) 1.07 (0.86–1.33) 0.51
Carotene (μg/d)e
Cut-point 1470 2139 2796 3696
Cases/controls 234/593 230/599 223/604 237/591 252/575
Odds ratio (95% CI) 1.00 0.96 (0.76–1.20) 0.88 (0.69–1.11) 0.95 (0.75–1.20) 0.96 (0.76–1.22) 0.84
Lycopene (μg/d)e
Cut-point 350 775 1303 2140
Cases/controls 217/596 236/577 258/554 237/576 213/599
Odds ratio (95% CI) 1.00 1.10 (0.88–1.38) 1.17 (0.94–1.47) 1.02 (0.81–1.28) 0.85 (0.67–1.07) 0.28
Vitamin B-6 (mg/d)
Cut-point 1.72 2.04 2.34 2.76
Cases/controls 306/743 339/710 347/713 338/700 387/662
Odds ratio (95% CI) 1.00 1.12 (0.91–1.37) 1.16 (0.94–1.42) 1.09 (0.88–1.35) 1.26 (1.00–1.58) 0.20
Folate (μg/d)
Cut-point 218 261 304 362
Cases/controls 336/713 338/711 327/722 369/680 347/702
Odds ratio (95% CI) 1.00 1.00 (0.82–1.21) 1.03 (0.84–1.26) 1.21 (0.98–1.49) 1.04 (0.83–1.30) 0.69
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Dietary intake and risk of prostate cancer by detection method
and disease stage
The risk of prostate cancer detected clinically or by PSA in relation
to dietary intakes is shown in Table 5. There was no signiﬁcant
heterogeneity in associations according to method of diagnosis,
except for vitamin D, but vitamin D was not signiﬁcantly
associated with risk for either clinically or PSA-detected cancer.
The risk of prostate cancer across food and nutrient groups
(Table 6) shows that there was no signiﬁcant heterogeneity for any
of the foods or nutrients by disease stage.
DISCUSSION
Prostate cancer risk in middle-aged and older men was not
associated with any of the 37 dietary components examined in
this comprehensive analysis based on food diaries (records).
There was weak evidence of heterogeneity of risk for
vitamin D between clinically and screen-detected disease,
but this ﬁnding may be due to chance. The main strengths
of this study are its size and diversity through pooling over
1700 prostate cancer cases from ﬁve predominantly population-
based UK studies with adjustment for clinical and demographic
confounders and the capacity to compare clinically and screen-
detected estimates of risk. Dietary records were comple-
ted prior to men’s knowledge of disease status in the
prospective cohorts, or prior to biopsies in ProtecT, thus excluding
recall bias.
This evaluation of prostate cancer risk and dietary factors is also
one of the few studies to examine intakes derived from food
diaries rather than FFQs. Biomarker validation studies have shown
Table 4. (Continued)
Food group, food or nutrienta Food or nutrient intake (increasing quintiles except where indicated) P value for trendb
1 (referent) 2 3 4 5
Vitamin B-12 (μg/d)
Cut-point 3.18 4.17 5.24 7.15
Cases/controls 338/711 345/704 340/709 356/693 338/711
Odds ratio (95% CI) 1.00 1.02 (0.84–1.24) 0.99 (0.81–1.21) 1.04 (0.85–1.27) 1.03 (0.83–1.26) 0.42
Vitamin C (mg/d)
Cut-point 45.6 65.0 88.6 125.2
Cases/controls 346/703 343/706 333/716 331/718 364/685
Odds ratio (95% CI) 1.00 1.06 (0.87–1.28) 0.95 (0.78–1.16) 0.99 (0.81–1.21) 1.05 (0.86–1.29) 0.63
Vitamin D (μg/d)
Cut-point 1.85 2.73 3.76 5.26
Cases/controls 334/715 346/703 340/709 347/702 350/699
Odds ratio (95% CI) 1.00 1.13 (0.93–1.37) 1.09 (0.90–1.34) 1.06 (0.87–1.30) 1.09 (0.88–1.33) 0.84
Vitamin E (mg/d)
Cut-point 7.1 9.0 11.1 14.1
Cases/controls 381/668 336/713 325/724 334/715 341/708
Odds ratio (95% CI) 1.00 0.90 (0.74–1.09) 0.89 (0.73–1.09) 0.90 (0.73–1.11) 1.02 (0.81–1.27) 0.55
Calcium (mg/d)
Cut-point 659 798 928 1112
Cases/controls 362/687 337/712 328/721 366/683 324/725
Odds ratio (95% CI) 1.00 0.98 (0.80–1.19) 0.96 (0.78–1.17) 1.20 (0.97–1.49) 1.00 (0.79–1.28) 0.53
Iron (mg/d)
Cut-point 9.9 11.7 13.6 15.9
Cases/controls 366/683 335/714 334/715 348/702 334/714
Odds ratio (95% CI) 1.00 0.92 (0.75–1.12) 0.92 (0.75–1.14) 1.01 (0.81–1.26) 0.97 (0.76–1.24) 0.97
Magnesium (mg/d)
Cut-point 248 292 334 390
Cases/controls 339/710 358/691 316/733 352/697 352/697
Odds ratio (95% CI) 1.00 1.10 (0.90–1.34) 0.90 (0.73–1.11) 0.99 (0.80–1.24) 1.02 (0.79–1.31) 0.63
Selenium (μg/d)
Cut-point 49.3 61.0 73.2 89.1
Cases/controls 319/730 316/733 376/673 335/714 371/678
Odds ratio (95% CI) 1.00 0.93 (0.76–1.14) 1.19 (0.98–1.46) 0.93 (0.76–1.15) 0.95 (0.76–1.19) 0.95
Zinc (mg/d)
Cut-point 7.4 8.7 9.8 11.4
Cases/controls 347/702 327/722 369/681 341/707 333/716
Odds ratio (95% CI) 1.00 0.94 (0.77–1.15) 1.07 (0.87–1.32) 0.93 (0.74–1.15) 0.89 (0.70–1.14) 0.77
aConditional logistic regression adjusted for age, BMI, socioeconomic, smoking and marital status, diabetes and energy intake. bP values relate to tests for
trend obtained for continuous intake variable. cFirst and second quintiles (and thirdd) combined due to large proportion of non-consumers. eUnknown for
some participants. fAlcohol intake in ﬁve categories (o1, 1–9, 10–19, 20–39, ⩾ 40 g/d).
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that food diaries are more accurate than FFQs for estimating some
nutrients.27,28 Pooling ﬁve studies may have potentially intro-
duced non-differential errors in nutrient intakes across the studies,
but the consortium provided training, protocols and data-
checking software to enhance consistency. We collected data on
entire cohorts and utilised a nested matched case-control analysis
to accommodate the resources required for diary coding, but this
reduced the power to identify weak associations compared with a
complete cohort analysis.
Limitations of these analyses include the inability to adjust for
individual social class, which potentially created a confounder in
the cohort studies as prostate cancer testing is more frequent in
afﬂuent individuals.29 Prostate cancer screening history was
unavailable for the cohorts, although PSA testing rates are
probably low as there is no formal UK screening programme (UK
ﬁgures are 4–6%19,30) and less than 15% had received a prior
test in the ProtecT study.17 All ProtecT controls with a PSA
⩾ 3.0 ng/ml had a negative biopsy result, thus reducing
misattribution bias (disease risk increases with PSA values), but
the absence of pathological conﬁrmation of disease-free status
for the majority of these controls is an unavoidable limitation,
which might attenuate diet and prostate cancer associations
because some controls will have undiagnosed disease (based on
autopsy data31). Clinical stage was missing for the NHSD and
Whitehall studies, which reduced the power to examine
differences by stage (although they contributed fewest cases),
and it was impossible to examine the associations of diet
subdivided by Gleason grade. Some differences (for example,
diary duration) could not be rectiﬁed in the analysis, as these
studies were established before the diet consortium, and some
confounders relevant to prostate cancer were not collected in all
studies, for example, family history of cancer, or were measured
in ways that did not allow pooling (for example, physical
activity). We utilised standardised dietary coding systems, which
increased exposure quantiﬁcation consistency, although hetero-
geneity in measurement duration could have also potentially
modiﬁed any associations. All dietary data instruments have
limitations, which we aimed to minimise where possible;
differential misclassiﬁcation through using a prospective design
and food diaries to reduce measurement error, although some
non-differential misclassiﬁcation will exist for estimated diet
constituents. Participants were predominantly white, thus
potentially limiting the wider generalisability to other ethnic
populations.
A recent meta-analysis of dietary factors and supplements and
prostate cancer risk has concluded that the intake of red and well-
Table 5. Odds ratios for prostate cancer diagnosis with dietary intake by cancer detection method
Food or nutrient intake (1 s.d.)a All studies
N = 1717/3258b
Clinically-detected(4 studies)
N = 663/2267b
PSA-detected (ProtecT study)
N = 1054/1261b
P value for
heterogeneityc
Red meat (31.3 g/d) 1.00 (0.94–1.07) 0.96 (0.87–1.06) 1.04 (0.95–1.13) 0.25
Processed meat (21.8 g/d) 1.00 (0.94–1.07) 0.98 (0.89–1.08) 1.02 (0.94–1.11) 0.55
Red and processed meat (39.8 g/d) 1.00 (0.94–1.07) 0.96 (0.86–1.06) 1.04 (0.96–1.14) 0.20
Poultry (25.1 g/d) 1.01 (0.95–1.07) 1.05 (0.96–1.15) 0.98 (0.90–1.06) 0.27
White ﬁsh (17.4 g/d) 1.02 (0.96–1.08) 1.02 (0.93–1.11) 1.02 (0.93–1.11) 0.99
Oily ﬁsh (21.7 g/d) 1.01 (0.95–1.07) 0.94 (0.86–1.03) 1.06 (0.97–1.15) 0.08
Milk (144 g/d) 1.03 (0.97–1.10) 1.06 (0.97–1.16) 1.00 (0.91–1.10) 0.37
Cheese (17.2 g/d) 0.96 (0.90–1.03) 0.96 (0.87–1.05) 0.96 (0.88–1.06) 0.93
Yogurt (44.5 g/d) 0.98 (0.93–1.04) 0.96 (0.87–1.07) 0.99 (0.92–1.07) 0.64
Fruit and vegetables (172 g/d) 0.99 (0.92–1.05) 1.06 (0.97–1.16) 0.93 (0.85–1.03) 0.06
Energy intake (2.10 MJ/d) 1.01 (0.95–1.08) 1.06 (0.96–1.16) 0.98 (0.89–1.07) 0.22
Protein (2.7% energy) 1.01 (0.95–1.09) 1.03 (0.92–1.16) 1.01 (0.92–1.10) 0.74
Protein from dairy products (1.3% energy) 1.00 (0.94–1.06) 1.03 (0.94–1.13) 0.97 (0.89–1.06) 0.38
Carbohydrate (6.8% energy) 0.98 (0.92–1.05) 1.03 (0.93–1.13) 0.95 (0.87–1.04) 0.26
Total fat (5.4% energy) 1.01 (0.95–1.07) 0.99 (0.90–1.09) 1.02 (0.94–1.11) 0.61
Saturated fat (3.0% energy) 1.00 (0.94–1.06) 0.98 (0.89–1.08) 1.01 (0.92–1.09) 0.73
Monounsaturated fat (2.1% energy) 1.01 (0.95–1.08) 1.01 (0.92–1.11) 1.02 (0.94–1.11) 0.88
Polyunsaturated fat (1.7% energy) 1.01 (0.95–1.07) 0.98 (0.90–1.08) 1.03 (0.95–1.13) 0.42
n-6 fatty acids (1.8% energy)d 0.97 (0.90–1.05) 0.98 (0.89–1.08) 0.95 (0.83–1.10) 0.77
n-3 fatty acids (0.27% energy)d 1.01 (0.94–1.09) 1.02 (0.92–1.13) 1.01 (0.91–1.13) 0.88
Ratio n-6:n-3 (3.7)d 0.99 (0.92–1.06) 0.97 (0.89–1.06) 1.02 (0.90–1.16) 0.55
Alcohol (21.6 g/d) 1.00 (0.93–1.06) 0.97 (0.88–1.07) 1.02 (0.93–1.11) 0.49
Dietary ﬁbre (6.0 g/d) 0.97 (0.90–1.04) 1.04 (0.94–1.14) 0.92 (0.83–1.02) 0.09
Retinol (1055 μg/d) 1.02 (0.96–1.09) 1.04 (0.96–1.12) 1.00 (0.90–1.12) 0.62
Carotene (1568 μg/d)d 1.01 (0.94–1.08) 1.05 (0.96–1.15) 0.94 (0.82–1.07) 0.17
Lycopene (1978 μg/d)d 0.96 (0.89–1.03) 0.94 (0.84–1.05) 0.97 (0.88–1.07) 0.68
Vitamin B6 (0.67 mg/d) 1.05 (0.98–1.13) 1.09 (0.98–1.21) 1.04 (0.94–1.15) 0.54
Folate (90 μg/d) 1.01 (0.94–1.09) 1.05 (0.95–1.16) 1.00 (0.90–1.10) 0.46
Vitamin B12 (3.97 μg/d) 1.03 (0.96–1.09) 1.06 (0.98–1.15) 0.99 (0.89–1.09) 0.28
Vitamin C (52.8 mg/d) 1.02 (0.95–1.08) 1.02 (0.92–1.12) 1.02 (0.94–1.11) 0.91
Vitamin D (2.77 μg/d) 1.01 (0.95–1.07) 0.92 (0.83–1.03) 1.06 (0.98–1.15) 0.04
Vitamin E (4.9 mg/d) 1.02 (0.95–1.10) 1.01 (0.91–1.11) 1.05 (0.94–1.18) 0.55
Calcium (283 mg/d) 1.03 (0.95–1.11) 1.05 (0.94–1.18) 0.99 (0.88–1.11) 0.46
Iron (3.9 mg/d) 1.00 (0.93–1.08) 1.00 (0.89–1.12) 1.02 (0.92–1.15) 0.75
Magnesium (91 mg/d) 0.98 (0.90–1.06) 1.02 (0.91–1.14) 0.96 (0.85–1.08) 0.48
Selenium (34.5 μg/d) 1.00 (0.94–1.07) 0.95 (0.85–1.07) 1.04 (0.96–1.13) 0.22
Zinc (2.53 mg/d) 0.99 (0.91–1.07) 1.03 (0.92–1.15) 0.96 (0.85–1.08) 0.39
aConditional logistic regression adjusted for age, BMI, socioeconomic, smoking and marital status, diabetes and energy intake. bNumber of cases and controls.
cTest of heterogeneity of trends between cohort studies (mostly clinically-detected disease) and ProtecT (PSA-detected disease). dUnknown for some
participants.
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done meat, fat and milk should be limited, whereas lycopene,
green tea and potentially soy-containing products may be
preventative.6 These dietary components were not associated in
this study with clinically or screen-detected disease, or with
disease stage (green tea and soy products were not evaluated).
However, recent evidence that ProtecT participants who
consumed at least 10 portions of tomatoes weekly showed an
18% reduced risk of developing prostate cancer supports the
meta-analyses recommendations.32 Previously, the EPIC con-
sortium found an increased prostate cancer risk with the highest
quartiles of dairy protein,33 but no association with dietary fat
(mostly using FFQs).32,34 Data from the US Health Professionals
study based on clinically detected cases found no association
between calcium intake and localised prostate cancer (mea-
sured with FFQs) but a positive association with advanced
disease.35 Conversely, calcium intake was related to an increased
risk of localised disease with screen-detected cases in the US
PLCO trial.36
The evidence for a link between obesity and fatal prostate
cancer4 is strengthening and energy intake might be on that
causal pathway. An association between energy intake and
advanced disease was shown in a meta-analysis for studies with
disease stage with a combined odds ratio of 1.6 for advanced
disease.37 In this study, there was no overall relationship between
energy intake and prostate cancer nor heterogeneity in the risk of
disease by stage (P= 0.07); the association with advanced disease
was positive (23% increase) but did not reach conventional
statistical signiﬁcance (95% CI 1.00–1.51).
The ﬁnding of weak evidence of heterogeneity in the
association of vitamin D with risk between clinically and screen-
detected disease may merit further investigation. The precision of
estimates of foods consumed irregularly, such as oily ﬁsh, a good
source of vitamin D, may be lower in food diaries than in
questionnaires. Vitamin D levels are also related to sunlight
exposure, making serological assessments more comprehensive.
In the ProtecT study, deﬁciency in vitamin D (circulating
concentration o12 ng/ml) was associated with a greater risk of
aggressive prostate cancer (higher grade or stage),38 which would
be more prevalent in clinically detected cases, but the recent
meta-analysis does not support vitamin D supplementation,
except for deﬁciency.6
There was no association of overall diet (assessed using FFQs)
and screen-detected prostate cancer in the US PCPT trial nor in the
Swedish study.39–40 Food diary data from 133 prostate cancer
cases also revealed no association with diet and prostate cancer,
but a reduction with a Mediterranean-style diet rich in
Table 6. Odds ratios for prostate cancer with dietary intake by disease stage
Food or nutrient intake (1 s.d.)a Localised or advanced stage,
N=1503/2418b,c
Localised stage,
N= 1277/1952c
Advanced stage,
N=226/466c
P value for heterogeneity by
disease staged
Red meat (31.3 g/d) 1.01 (0.94–1.09) 1.04 (0.96–1.13) 0.83 (0.66–1.04) 0.06
Processed meat (21.8 g/d) 1.00 (0.93–1.08) 1.01 (0.93–1.09) 0.99 (0.80–1.24) 0.92
Red and processed meat (39.8 g/d) 1.01 (0.93–1.09) 1.04 (0.96–1.13) 0.85 (0.67–1.07) 0.11
Poultry (25.1 g/d) 0.99 (0.92–1.06) 0.99 (0.91–1.07) 0.99 (0.81–1.21) 0.96
White ﬁsh (17.4 g/d) 1.00 (0.93–1.08) 0.99 (0.92–1.08) 1.10 (0.90–1.35) 0.37
Oily ﬁsh (21.7 g/d) 1.02 (0.95–1.10) 1.02 (0.94–1.10) 1.06 (0.87–1.29) 0.71
Milk (144 g/d) 1.02 (0.95–1.11) 1.01 (0.93–1.10) 1.11 (0.92–1.35) 0.36
Cheese (17.2 g/d) 0.93 (0.86–1.01) 0.90 (0.83–0.99) 1.03 (0.84–1.26) 0.25
Yogurt (44.5 g/d) 0.96 (0.89–1.03) 0.96 (0.89–1.03) 1.01 (0.80–1.27) 0.65
Fruit and vegetables (172 g/d) 0.98 (0.91–1.06) 0.97 (0.89–1.05) 1.11 (0.90–1.36) 0.23
Energy intake (2.10 MJ/d) 1.03 (0.95–1.11) 1.00 (0.92–1.08) 1.23 (1.00–1.51) 0.07
Protein (2.7% energy) 1.01 (0.93–1.09) 1.01 (0.92–1.11) 1.00 (0.79–1.27) 0.96
Protein from dairy products (1.3% energy) 0.97 (0.90–1.04) 0.94 (0.87–1.02) 1.09 (0.88–1.34) 0.21
Carbohydrate (6.8% energy) 0.98 (0.91–1.06) 0.98 (0.90–1.07) 1.04 (0.83–1.29) 0.64
Total fat (5.4% energy) 1.05 (0.97–1.13) 1.04 (0.96–1.13) 1.03 (0.84–1.27) 0.93
Saturated fat (3.0% energy) 1.04 (0.96–1.12) 1.02 (0.94–1.11) 1.08 (0.88–1.34) 0.62
Monounsaturated fat (2.1% energy) 1.04 (0.97–1.12) 1.05 (0.97–1.13) 0.99 (0.81–1.22) 0.64
Polyunsaturated fat (1.7% energy) 1.04 (0.96–1.11) 1.05 (0.97–1.14) 0.94 (0.77–1.16) 0.33
n-6 fatty acids (1.8% energy)b 0.98 (0.89–1.07) 0.99 (0.90–1.10) 0.91 (0.73–1.13) 0.48
n-3 fatty acids (0.27% energy)b 1.01 (0.93–1.10) 1.02 (0.93–1.12) 0.96 (0.75–1.22) 0.67
Ratio n-6:n-3 (3.7)b 1.01 (0.92–1.10) 1.01 (0.92–1.12) 0.97 (0.79–1.20) 0.70
Alcohol (21.6 g/d) 0.97 (0.90–1.05) 0.97 (0.90–1.06) 0.93 (0.74–1.17) 0.72
Dietary ﬁbre (6.0 g/d) 0.98 (0.90–1.06) 0.96 (0.88–1.05) 1.14 (0.91–1.43) 0.17
Retinol (1055 μg/d) 1.03 (0.95–1.11) 1.02 (0.93–1.11) 1.09 (0.91–1.29) 0.50
Carotene (1568 μg/d)b 1.02 (0.93–1.11) 1.00 (0.91–1.11) 1.06 (0.84–1.35) 0.66
Lycopene (1978 μg/d)b 0.98 (0.90–1.06) 0.98 (0.90–1.07) 0.93 (0.72–1.19) 0.67
Vitamin B6 (0.67 mg/d) 1.02 (0.94–1.11) 1.02 (0.93–1.12) 1.08 (0.84–1.38) 0.70
Folate (90 μg/d) 1.01 (0.93–1.10) 1.00 (0.92–1.10) 1.08 (0.85–1.38) 0.58
Vitamin B12 (3.97 μg/d) 1.04 (0.97–1.12) 1.04 (0.96–1.13) 1.05 (0.86–1.29) 0.93
Vitamin C (52.8 mg/d) 1.00 (0.92–1.08) 1.00 (0.92–1.09) 0.99 (0.79–1.24) 0.93
Vitamin D (2.77 μg/d) 1.02 (0.95–1.09) 1.03 (0.96–1.12) 0.94 (0.74–1.19) 0.44
Vitamin E (4.9 mg/d) 1.03 (0.94–1.13) 1.04 (0.94–1.15) 0.97 (0.78–1.21) 0.57
Calcium (283 mg/d) 0.97 (0.88–1.07) 0.96 (0.86–1.06) 1.06 (0.82–1.37) 0.47
Iron (3.9 mg/d) 0.99 (0.91–1.09) 1.02 (0.92–1.12) 0.87 (0.67–1.13) 0.28
Magnesium (91 mg/d) 0.97 (0.89–1.07) 0.96 (0.87–1.06) 1.08 (0.83–1.41) 0.42
Selenium (34.5 μg/d) 1.00 (0.93–1.08) 0.99 (0.90–1.08) 0.99 (0.83–1.17) 0.99
Zinc (2.53 mg/d) 1.00 (0.91–1.10) 1.01 (0.91–1.12) 0.96 (0.73–1.26) 0.75
aConditional logistic regression adjusted for age, BMI, smoking, marital status, diabetes, socioeconomic status and energy intake. bStage unknown for
214 cases. cNumber of cases and controls. dTest of heterogeneity of trends between localised and advanced disease.
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monounsaturated fatty acids and vegetables/fruits and low in red
meats.41 A recent meta-analysis of adherence to a Mediterranean
diet and overall cancer risk showed a 4% risk reduction for
prostate cancer incidence.42
The natural history of prostate cancer remains poorly under-
stood, including the time points when dietary and environmental
factors may inﬂuence disease development or progression.43 This
study measured dietary intake prior to diagnosis and found no
major associations with prostate cancer risk, yet migrant studies
and international variation in prostate cancer incidence suggest
that dietary or other environmental components contribute to
disease risk. More recent evidence highlights a role of dietary
factors in disease progression, for example, fat intake may
inﬂuence prostate cancer mortality.44 Future studies will need to
extend measurement of dietary intake across the life course,
consider intermediary inﬂuences such as the insulin-like growth
factor axis and examine the role of obesity, which increases the
risk of aggressive prostate cancer, subsequent disease progression
and mortality.4
CONCLUSIONS
In summary, this large study revealed no strong evidence that
prostate cancer risk is associated with dietary intake measured
prior to diagnosis in middle-aged and older men.
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